Novartis’ head of drug development Vas Narasimhan talks about the company’s stake in CAR-T immunotherapy. These cell therapies are set to transform treatment of blood cancers – but questions ...

TOKYO (Reuters) -Swiss pharmaceutical giant Novartis says it is watching "very carefully" how the reciprocal tariff policy ...

The comprehensive restructuring of Novartis under new CEO Vas Narasimhan resulted in $15 billion in bolt-on acquisitions last year, and he wants to keep up that momentum. Speaking on Novartis ...

Vas Narasimhan is global head of drug development and chief medical officer at Novartis, and spoke to pharmaphorum at the company’s recent Q4 results conference. He says numerous pilot studies ...

The company says it conducted a thorough evaluation of internal and external candidates, but decided that Vasant Narasimhan, known as Vas, was the best candidate to take the company forward.

(Bloomberg) -- Moves by the incoming Trump Administration may be a boon to drugmakers, Novartis AG Chief Executive Officer Vas Narasimhan said, while concerns over vaccine policies and public ...

Swiss pharmaceutical giant Novartis (SIX:NOVN) is keeping a close eye on the U.S. tariff policy proposed by the Biden ...

TOKYO (Reuters) -Swiss pharmaceutical giant Novartis (NVS) will watch "very carefully" how the reciprocal tariff policy proposed by the United States unfolds in early April, Chief Executive Vas ...